AllSci News
Merck’s Keytruda-Padcev combo becomes first PD-1/ADC regimen for cisplatin-ineligible bladder cancer
The European Commission has approved Keytruda (pembrolizumab) in combination with Padcev (enfortumab vedotin) as perioperative treatment for adults with resectable muscle-invasive bladder…
Remix Therapeutics takes Nasdaq listing through Passage Bio reverse merger, USD 100m raise
Philadelphia-based Passage Bio (Nasdaq: PASG) and Watertown, Massachusetts-based Remix Therapeutics have announced a definitive all-stock merger agreement...
Eli Lilly doubles down on ProQR with USD 59.2m funding round
Netherlands-based ProQR Therapeutics N.V. (Nasdaq: PRQR) announced the pricing of a combined underwritten registered direct offering and concurrent private...
Taysha raises USD 200m to advance Rett syndrome gene therapy independently after Astellas exit
Dallas-based Taysha Gene Therapies (Nasdaq: TSHA) announced the pricing of an underwritten public offering of common stock and pre-funded warrants, raising...
Oblenio raises USD 62m to test tri-specific T-cell engager in autoimmune disease
Cambridge, Massachusetts-based Oblenio Bio, Inc. has closed an oversubscribed USD 62 million Series B financing round to advance LBL-051, its CD19/BCMA/CD3...
Henlius’ PD-1 Hetronifly adds new indication in 1st-line squamous lung cancer across EU
The European Commission has approved a new indication for Hetronifly (serplulimab), China-based Shanghai Henlius Biotech’s (HKEX: 02696) anti-PD-1 antibody, covering first-line treatment…
CStone completes global rollout of PD-L1 sugemalimab with Australia-New Zealand deal
CStone Pharmaceuticals (HKEX: 2616) has completed its geographic rollout of sugemalimab by signing an exclusive commercialization agreement with Arrotex...
Gilead expands Trodelvy into first-line triple-negative breast cancer with dual FDA approvals
The US FDA approved Trodelvy (sacituzumab govitecan-hziy) for two first-line indications in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC), marking…
Merck KGaA to aquire life sciences tool firm Bio-Techne for USD 11.3b
Germany-based Merck KGaA agreed to acquire Minneapolis-based Bio-Techne Corporation (Nasdaq: TECH) in an all-cash transaction valued at USD 11.3 billion...
Novartis bets USD 1.9b on Antares' covalent chemistry platform for undruggable cancer targets
Novartis has committed up to USD 1.905 billion to access Boston-based Antares Therapeutics' covalent small molecule discovery engine, in one of the largest...
Immunomic's self-amplifying RNA vaccine enters human testing in TNBC
Immunomic Therapeutics Initiates First-in-Human saRNA Cancer Vaccine Trial in Triple-Negative Breast Cancer
BIDMC wins NIH grant to study ADAMTS13 deficiency beyond rare clotting disorder
Beth Israel Deaconess Medical Center (BIDMC) has received a USD 1.63 million NIH R01 grant from the National Heart, Lung, and Blood Institute to investigate...
Brigham and Women's investigates "affinity birth" in B cells to expand antibody repertoire plasticity
Brigham and Women's Hospital has received a USD 3 million NIH R01 grant from the National Institute of Allergy and Infectious Diseases to investigate...
Viking's dual amylin-calcitonin agonist enters clinic to advance combo obesity strategy
San Diego-based Viking Therapeutics (Nasdaq: VKTX) has initiated a Phase I single ascending dose trial of VK3019, an internally developed dual amylin and...
Leyden Labs secures EUR 40m to advance intranasal antibody defense against respiratory viruses
Netherlands-based Leyden Laboratories B.V. (Leyden Labs) announced a €40 million (approximately USD 43.6 million) private placement from a geographically...
The AllSci Brief
Systematic R&D and deal news. Daily.